Evidence suggests no increased risk The use of glucagon-like peptide-1 (GLP-1) receptor agonists has surged in recent years, driven by their benefits in glucose control in type 2 diabetes, weight ...

For older adults with type 2 diabetes, use of GLP-1 RAs is associated with a modestly lower risk for depression compared with DPP-4i use.

While one study found lower rates of preterm birth alongside higher rates of hypertensive disorders, another found fewer ...

A study comparing GLP-1 users to others on antidiabetic drugs showed no added risk once confounders were accounted for.

The WEGOVY market has experienced significant growth, driven by rising obesity rates and increasing demand for effective weight-loss treatments. Novo Nordisk's blockbuster drug has seen strong ...

The use of glucagon-like peptide-1 receptor agonists , such as semaglutide—marketed under brand names like Wegovy and Ozempic—has surged among adolescents and young adults. Between 2020 and 2023, the ...

RAs are transforming obesity treatment, demonstrating substantial weight loss and metabolic improvements with lifestyle ...

Use of GLP-1 receptor agonists to treat type 2 diabetes is not associated with an increased risk of suicidality compared with ...

For individuals with type 2 diabetes (T2D), semaglutide is associated with a modestly increased risk for nonarteritic ...

On his Instagram profile, the “Queer Eye” star Jonathan Van Ness detailed that he lost 30 kg with GLP-1 weight-loss ...

Objective—Glucagon-like peptide 1 (GLP-1) exerts beneficial antidiabetic actions via effects on pancreatic β- and α-cells. Previous studies have focused on the improvements in β-cell function ...

A new study adds on to the growing evidence of potential mental health benefits of GLP-1RAs, along with other benefits it ...